Curaleaf International

What it is

Curaleaf International is the European subsidiary of Curaleaf Holdings, Inc., a US-based multistate cannabis operator listed on the Canadian Securities Exchange under the ticker CURA ^[1]. The international division is headquartered in London and operates across several European medical cannabis markets, including the United Kingdom, Germany, Italy, Poland, and Portugal ^[1][2].

The business focuses on medical cannabis: cultivation, extraction, manufacturing of pharmaceutical-grade products (mainly dried flower and oils), import/export logistics, and distribution to pharmacies through prescription channels. It does not operate in adult-use recreational markets in Europe, because no such legal market existed at the federal level in any of its core countries as of the last check, although Germany's 2024 cannabis reform changed the regulatory environment for non-medical possession and home cultivation without creating a commercial recreational market ^[3].

Ownership and corporate history

Curaleaf International began as EMMAC Life Sciences, a European medical cannabis company founded in 2017 ^[2]. In April 2021, Curaleaf Holdings announced the acquisition of EMMAC for approximately $286 million in cash and stock, rebranding it as Curaleaf International ^[2][4]. The deal gave Curaleaf its European footprint, including the Terra Verde cultivation facility in Portugal and distribution channels in Germany and the UK ^[2][4].

In 2023, Curaleaf Holdings announced a corporate reorganisation and listing move from the CSE toward eventual listings on senior exchanges; investors should check current parent filings for the most recent capital structure ^[1]. Curaleaf International remains a wholly owned subsidiary of Curaleaf Holdings as of the last check.

Market and product focus

Curaleaf International's main consumer-facing brand in Germany is Adven, which markets prescription medical cannabis flower and oil products through German pharmacies under the German narcotics prescription (BtM-Rezept) framework ^[5]. In the UK, the company supplies medical cannabis to private clinics and pharmacies under the post-2018 specials regime that allows specialist doctors to prescribe unlicensed cannabis-based products for medicinal use ^[6].

Its Portuguese operation, Terra Verde near Setúbal, is a EU-GMP licensed cultivation and processing site that supplies flower and extracts to European markets ^[2]. The company has stated it also serves Italy and Poland's medical cannabis programs, though independent verification of specific volumes is limited.

This profile does not recommend any specific Curaleaf or Adven product. Patients should make prescribing decisions with their clinicians.

Reputation, scale, and caveats

Curaleaf International is frequently described in industry trade press as one of the largest vertically integrated medical cannabis operators in Europe ^[7]. That framing is plausible given the parent company's resources and the Portuguese cultivation footprint, but specific claims about being "the largest" should be treated with caution: Europe's medical cannabis market is fragmented, audited country-by-country volumes are scarce, and competitors (Aurora, Tilray, Cantourage, Demecan and others) make similar claims Disputed.

The Adven brand is well known to German medical cannabis patients but, as with all prescription products, patient experience varies and pharmacy availability of specific cultivars changes frequently. There are no widely recognised independent quality awards specific to medical cannabis brands in Europe comparable to those in adult-use markets.

Controversies and regulatory issues

In November 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) suspended Curaleaf International's UK manufacturer/importer licence after an inspection raised compliance concerns; the company said it was working with the regulator and the suspension affected its UK supply temporarily ^[8]. The licence was subsequently reinstated, but the episode is a useful reminder that medical cannabis operators are subject to ongoing pharmaceutical regulatory oversight and that supply continuity is not guaranteed.

Separately, parent company Curaleaf Holdings has faced US regulatory and shareholder scrutiny over CBD product marketing claims (an FDA warning letter in 2019) and over financial disclosures ^[9]. Those actions concern the US parent, not the European subsidiary directly, but they are part of the corporate group's record.

Availability and legal-market notes

Curaleaf International products are only legally available through medical cannabis channels in countries where the company holds the relevant licences and where a clinician has issued a prescription. Curaleaf International does not sell directly to consumers, and it does not operate in adult-use recreational markets in Europe.

Availability of specific Adven cultivars in German pharmacies fluctuates based on import schedules, cultivation cycles, and demand. Patients in the UK access products through specialist private clinics, since NHS prescribing of unlicensed cannabis products remains rare ^[6].

What to verify before relying on brand claims

Before treating any marketing claim about Curaleaf International or Adven as fact, check:

• Current licensing status with the relevant national regulator (MHRA in the UK, BfArM in Germany, Infarmed in Portugal).
• Parent company filings at Curaleaf Holdings investor relations and SEDAR+ for segment-level financials, which are more reliable than press releases ^[1].
• Product COAs (certificates of analysis) for cannabinoid content and contaminant testing on any specific batch you are prescribed.
• Clinician guidance for whether a Curaleaf/Adven product is appropriate for your condition, rather than relying on brand marketing.

Profile last checked: 2024. Corporate structure, licensing, and product availability change frequently in European medical cannabis.

Sources

How this page was made